Compare WRAP & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WRAP | ETON |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.4M | 498.8M |
| IPO Year | N/A | 2018 |
| Metric | WRAP | ETON |
|---|---|---|
| Price | $2.17 | $16.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | ★ 420.6K | 240.7K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $4,133,000.00 | ★ $70,316,000.00 |
| Revenue This Year | N/A | $107.23 |
| Revenue Next Year | N/A | $29.72 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 102.77 |
| 52 Week Low | $1.20 | $11.09 |
| 52 Week High | $3.00 | $23.00 |
| Indicator | WRAP | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 44.16 | 53.73 |
| Support Level | $2.09 | $16.27 |
| Resistance Level | $2.36 | $16.95 |
| Average True Range (ATR) | 0.19 | 0.64 |
| MACD | -0.04 | 0.16 |
| Stochastic Oscillator | 7.59 | 75.95 |
Wrap Technologies Inc is a public safety technology and services company that delivers safe and effective policing solutions to law enforcement and security personnel worldwide. The firm develops policing solutions to law enforcement and security personnel. Its BolaWRAP 150 Remote Restraint device is a patented, hand-held tool that discharges a Kevlar cord to restrain noncompliant individuals from a range of 10-25 feet. The group operates in the Americas, Europe, the Middle East, Africa and the Asia Pacific.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.